COVID-19 Infection in patients with Chronic Kidney Disease: Prognosis and Pharmacological Management
Garazhayeva L. Gaipov A. Kauysheva A.
July 2024Research Journal of Pharmacy and Technology
Research Journal of Pharmacy and Technology
2024#17Issue 73098 - 3108 pp.
Background: Since late 2019, chronic renal disease, which complicates COVID-19 infection, has affected millions globally. Aim: To find key findings, prognosis, associated factors, outcomes, gaps, and recommendations related to COVID-19 in individuals with CKD. Methdology: A narrative review using keywords (COVID-19 OR SARS-CoV-2 OR 2019-nCoV Infections) AND (Chronic Kidney Disease OR CKD OR End-Stage Renal Disease OR Chronic Renal Failure OR Chronic Renal Insufficiency). Results: Analyzed systematic reviews, case-control studies, meta-analyses, observational, retrospective, randomised controlled trials, and case reports. The meta-analysis was conducted using a Random-Effects. The Q-statistic test for heterogeneity was conducted, with 11 degrees of freedom The pooled effect size estimate is 0.6663. The pooled estimate shows a statistically significant impact, with a 95% confidence interval ranging from 0.1834 to 1.1493. Age and comorbidities accelerate disease progression. Scientific Novelity: Briefly discusses how CKD affects COVID-19 patients. Conclusion: CKD greatly increases all-cause mortality and morbidity.
Chronic kidney disease , CKD , Clinical predictors , Corona virus , COVID-19 , Management , Prognosis
Text of the article Перейти на текст статьи
Department Мedicine, Kazakhstan Medical University «KSPH», Almaty, Kazakhstan
School of Medicine at the Nazarbayev University, Astana, Kazakhstan
Department Public, HealthKazakhstan Medical University «KSPH», Almaty, Kazakhstan
Department Мedicine
School of Medicine at the Nazarbayev University
Department Public
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026